Source: GlobeNewswire

Press Release: Paratek : Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million ---- Oral-only CABP Pharmacokinetics Study Initiated--

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Evan Loh's photo - CEO of Paratek

CEO

Evan Loh

CEO Approval Rating

90/100

Paratek is a biopharmaceutical company that develops antibiotic drugs to treat bacterial pneumonia in adults. Read more